Provectus Biopharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
Edward Pershing amends Schedule 13D, reporting 11.61% beneficial ownership of Provectus Biopharmaceuticals common stock, including convertible notes and options.
OQB
Dominic Rodrigues, Vice-Chairman and President of Provectus Biopharmaceuticals, Inc., increased his beneficial ownership to 5.67% through recent stock option grants and preferred stock conversions.
OQB
Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, increased his beneficial ownership to 10.56% through recent convertible note purchases and conversions.